Although not of relevance in the general context of Cushing’s disease, isolated reports of somatic TP53 and ATXR mutations in aggressive corticotroph tumors and carcinomas, suggest that genetic TP53 screening and/or ATXR immunohistochemistry in selected patient subpopulations may indicate those more likely to require increased surveillance. Here, TP53 is linked to carcinoma.